RE:RevenueThe revenue is going to come from the growers involved in the trials. They will be first at the gate. The $ amount in Q3 is probably not the catalyst for the share price. Once we have sales we have confirmation of a marketable asset. Historically share prices surge once a company turns this important corner.I think with the rebranding of the company coming at the end of the month and the publication of trial results the stock will gain some healthy momentum even before Q3..